ID

DB10584||

名称

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

描述

cas号

308079-75-6

唯一标识码

IRH51QN26H

状态

组

approved,investigational,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

消除途径

种类

Actively Acquired Immunity

Antiinfectives for Systemic Use

Bacterial Vaccines
D001428
Biological Products
D001688
Complex Mixtures
D045424
Diphtheria
D004165
Diphtheria Vaccines

Inactivated Corynebacterium Diphtheriae Vaccine

Toxoids
D014121
Vaccines
D014612

盐类

蛋白质结合

清除

同义词

language:english; code:; name;Diphtheria toxoid
language:english; code:; name;Diphtheria toxoid adsorbed

国际品牌

配送量

产品

name:Adacel TDaP
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-400
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-06-10
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125111
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Adacel TDaP TDaP
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-848
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-14
ended-marketing-on:2016-03-29
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125111
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Boostrix
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1831
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA125106
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Boostrix
labeller:GlaxoSmithKline Biologicals SA
ndc-id:
ndc-product-code:58160-842
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA125106
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Boostrix
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1377
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA125106
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1079
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-06-10
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125111
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:D2t5
labeller:ID Biomedical Corporation of Quebec
ndc-id:
ndc-product-code:
dpd-id:01915274
ema-product-code:
ema-ma-number:
started-marketing-on:1991-12-31
ended-marketing-on:2005-08-03
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Daptacel
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-286
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2002-05-14
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA103666
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Decavac
labeller:Sanofi Pasteur Limited
ndc-id:
ndc-product-code:49281-291
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2004-03-24
ended-marketing-on:2016-05-19
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA103921
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diphtheria and Tetanus Toxoids Adsorbed
labeller:Aventis Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:00521841
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:2001-07-19
dosage-form:Liquid
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Diphtheria and Tetanus Toxoids Adsorbed
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-225
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-29
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA103944
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diphtheria and Tetanus Toxoids Adsorbed
labeller:Sanofi Pasteur Limited
ndc-id:
ndc-product-code:49281-278
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1984-09-18
ended-marketing-on:2013-03-18
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA103944
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Diphtheria and Tetanus Toxoids With Pertussis Vaccine Adsorbed
labeller:Aventis Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:00483648
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:2001-07-19
dosage-form:Liquid
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Diphtheria Toxoid
labeller:Aventis Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:00074853
ema-product-code:
ema-ma-number:
started-marketing-on:1925-12-31
ended-marketing-on:2001-07-19
dosage-form:Liquid
strength:
route:Subcutaneous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Diphtheria Toxoid for Reaction Test 0.2lf/ml
labeller:Aventis Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:01904264
ema-product-code:
ema-ma-number:
started-marketing-on:1955-01-01
ended-marketing-on:2000-04-06
dosage-form:Liquid
strength:
route:Intradermal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Diphtheria Toxoid for Schick Control 0.2lf/ml
labeller:Connaught Laboratories Ltd.
ndc-id:
ndc-product-code:
dpd-id:00074837
ema-product-code:
ema-ma-number:
started-marketing-on:1925-12-31
ended-marketing-on:1996-09-10
dosage-form:Liquid
strength:
route:Intradermal
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Diphtheria Toxoid Immunization Of Reactors
labeller:Aventis Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:00074845
ema-product-code:
ema-ma-number:
started-marketing-on:1933-12-31
ended-marketing-on:2001-07-19
dosage-form:Liquid
strength:
route:Subcutaneous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Infanrix
labeller:GlaxoSmithKline Biologicals SA
ndc-id:
ndc-product-code:58160-810
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA103647
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Infanrix
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-2883
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:BLA103647
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Kinrix
labeller:GlaxoSmithKline Biologicals SA
ndc-id:
ndc-product-code:58160-812
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-07-09
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125260
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pediarix
labeller:GlaxoSmithKline Biologicals SA
ndc-id:
ndc-product-code:58160-811
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-24
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA103907
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentacel
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-511
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-06-20
ended-marketing-on:
dosage-form:
strength:
route:Intramuscular
fda-application-number:BLA125145
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Pentacel
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-06-20
ended-marketing-on:
dosage-form:
strength:
route:Intramuscular
fda-application-number:BLA125145
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quadracel
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-564
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-24
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125525
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Quadracel
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-562
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-24
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125525
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Td Adsorbed
labeller:Sanofi Pasteur Limited
ndc-id:
ndc-product-code:
dpd-id:00514462
ema-product-code:
ema-ma-number:
started-marketing-on:1980-12-31
ended-marketing-on:
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tdvax
labeller:GRIFOLS USA, LLC
ndc-id:
ndc-product-code:13533-131
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-07-01
ended-marketing-on:
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA101322
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tdvax
labeller:MassBiologics
ndc-id:
ndc-product-code:14362-0111
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1970-07-27
ended-marketing-on:
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA101322
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tenivac
labeller:Sanofi Pasteur Inc.
ndc-id:
ndc-product-code:49281-215
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-12-08
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA103171
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tetanus and Diphtheria Toxoids Adsorbed
labeller:Merck Sharp & Dohme Limited
ndc-id:
ndc-product-code:0006-4133
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1970-07-27
ended-marketing-on:2014-06-02
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA101322
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tetanus and Diphtheria Toxoids Adsorbed
labeller:Akorn
ndc-id:
ndc-product-code:17478-131
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-02-15
ended-marketing-on:2017-03-14
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA101322
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tetanus and Diphtheria Toxoids Adsorbed
labeller:Remedy Repack
ndc-id:
ndc-product-code:61786-433
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-12
ended-marketing-on:2015-11-17
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA101322
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Tetanus and Diphtheria Toxoids Adsorbed for Adult Use
labeller:Lederle Labs, Division of American Cyanamid Co
ndc-id:
ndc-product-code:
dpd-id:02215098
ema-product-code:
ema-ma-number:
started-marketing-on:1998-12-31
ended-marketing-on:2001-04-23
dosage-form:Suspension
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tri-immunol Liq Im
labeller:Lederle Labs, Division of American Cyanamid Co
ndc-id:
ndc-product-code:
dpd-id:02019981
ema-product-code:
ema-ma-number:
started-marketing-on:1993-12-31
ended-marketing-on:2001-06-05
dosage-form:Liquid
strength:
route:Intramuscular
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Tripedia
labeller:Sanofi Pasteur Limited
ndc-id:
ndc-product-code:49281-298
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1992-08-20
ended-marketing-on:2013-03-13
dosage-form:Injection
strength:
route:Intramuscular
fda-application-number:BLA103922
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vaxelis
labeller:MSP Vaccine Company
ndc-id:
ndc-product-code:63361-243
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-12-21
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125563
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vaxelis
labeller:MCM Vaccine Co.
ndc-id:
ndc-product-code:63361-245
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-12-21
ended-marketing-on:2020-04-10
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125563
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Diphtheria and Tetanus Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tripedia
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tetanus and Diphtheria Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tetanus and Diphtheria Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Decavac
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Adacel TDaP TDaP
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tetanus and Diphtheria Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tdvax
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria and Tetanus Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Pediarix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Hepatitis B Vaccine (Recombinant) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Infanrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tdvax
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tenivac
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Pentacel
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Quadracel
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Infanrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Boostrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Boostrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Adacel TDaP
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Vaxelis
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen + Hepatitis B Vaccine (Recombinant) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Quadracel
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Boostrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Vaxelis
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen + Hepatitis B Vaccine (Recombinant) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Daptacel
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Pentacel
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis fimbriae 2/3 antigen + Bordetella pertussis pertactin antigen + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Kinrix
ingredients:Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) + Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Poliovirus type 1 antigen (formaldehyde inactivated) + Poliovirus type 2 antigen (formaldehyde inactivated) + Poliovirus type 3 antigen (formaldehyde inactivated)
name:Td Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:D2t5
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria and Tetanus Toxoids With Pertussis Vaccine Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Pertussis vaccine
name:Diphtheria and Tetanus Toxoids Adsorbed
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria Toxoid for Reaction Test 0.2lf/ml
ingredients:Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria Toxoid
ingredients:Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria Toxoid Immunization Of Reactors
ingredients:Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Tri-immunol Liq Im
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) + Pertussis vaccine
name:Tetanus and Diphtheria Toxoids Adsorbed for Adult Use
ingredients:Clostridium tetani toxoid antigen (formaldehyde inactivated) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
name:Diphtheria Toxoid for Schick Control 0.2lf/ml
ingredients:Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

包装者

生产者

价格

受影响的生物体

剂量

form:Injection, solution
route:Intramuscular
strength:2 Lf/0.5mL
form:Injection, suspension
route:Intramuscular
strength:2 Lf/0.5mL
form:Injection, suspension
route:Intramuscular
strength:5 ug/0.5mL
form:Injection
route:Intramuscular
strength:40 Lf
form:Injection, suspension
route:Intramuscular
strength:56 iu/1mL
form:Injection, suspension
route:Intramuscular
strength:8 ug/0.5mL
form:Suspension
route:Intramuscular
strength:2 IU/0.5ml
form:Injection, suspension
route:Intramuscular
strength:8 mcg/0.5ml
form:Injection, suspension
route:Intramuscular
strength:2.5 mcg
form:Suspension
route:Intramuscular
strength:8 cg
form:Injection, suspension
route:Intramuscular
strength:5 iu/0.5mL
form:Injection, suspension
route:
strength:30 iu/0.5mL
form:Suspension
route:Intramuscular
strength:
form:Injection
route:Intramuscular
strength:20 UI
form:Injection, suspension
route:Intramuscular
strength:
form:Liquid
route:Intramuscular
strength:
form:Liquid
route:Subcutaneous
strength:
form:Liquid
route:Intradermal
strength:
form:Injection, suspension
route:Parenteral
strength:6.25 Lf
form:Injection, suspension
route:Parenteral
strength:2 IU
form:Injection, suspension
route:Parenteral
strength:20 mcg
form:Injection, suspension
route:Intramuscular
strength:4 IU/0.5ml
form:Injection, suspension
route:Intramuscular
strength:20 UI
form:Injection, solution
route:Intramuscular
strength:20 IU
form:Injection, suspension
route:Intramuscular
strength:25 mcg/0.5ml
form:Suspension
route:Intramuscular
strength:2 IU
form:Injection, suspension
route:Intramuscular
strength:25 ug/0.5mL
form:Injection, powder, for suspension
route:Intramuscular
strength:25 mcg
form:Injection, powder, for suspension
route:Intramuscular
strength:30 UI
form:Suspension
route:Intramuscular
strength:30 UI
form:Injection, powder, for suspension
route:Intramuscular
strength:10 mcg
form:Injection, powder, for suspension
route:Intramuscular
strength:25 mcg/0.5ml
form:Injection, powder, for suspension
route:Intramuscular
strength:8 μg
form:Injection, suspension
route:Intramuscular
strength:40 [D'ag'U]/0.5mL
form:Solution
route:Intramuscular
strength:4 mcg
form:
route:Intramuscular
strength:
form:Injection
route:Intramuscular
strength:30 IU
form:Injection, powder, for suspension
route:Intramuscular
strength:30 IU/0.5ml
form:Injection, suspension
route:Intramuscular
strength:2 IU
form:Injection, suspension
route:Intramuscular
strength:20 IU/0.5ml
form:Injection, suspension
route:Intramuscular
strength:2 UI
form:Injection, suspension
route:Intramuscular
strength:40 IU/0.5mL
form:Injection, suspension
route:Intramuscular
strength:2 iu/0.5mL
form:Injection
route:Intramuscular
strength:40 IU
form:Injection, solution
route:Intramuscular
strength:40 IU/0.5mL
form:Injection, suspension
route:Intramuscular
strength:30 UI
form:Injection, suspension
route:Intramuscular
strength:30 IU
form:Injection, suspension
route:Intramuscular
strength:30 IU/0.5mL
form:Injection, suspension
route:Intramuscular; Subcutaneous
strength:2 IU/0.5ml
form:Injection
route:Intramuscular
strength:

atc代码

Diphtheria vaccines
BACTERIAL VACCINES
VACCINES
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00005
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00008
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00011
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00018
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00022
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00026
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00033
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00034
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00041
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00051
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
DB00056
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.
DB00059
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.
DB00065
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.
DB00068
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.
DB00069
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.
DB00072
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.
DB00073
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.
DB00074
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.
DB00075
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.
DB00078
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.
DB00081
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.
DB00087
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
DB00091
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.
DB00092
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
DB00095
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.
DB00098
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
DB00105
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.
DB00108
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.
DB00111
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.
DB00112
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
DB00120
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Phenylalanine.
DB00188
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib.
DB00242
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cladribine.
DB00262
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carmustine.
DB00276
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
DB00290
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bleomycin.
DB00291
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Chlorambucil.
DB00293
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Raltitrexed.
DB00305
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mitomycin.
DB00307
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bexarotene.
DB00309
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vindesine.
DB00322
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Floxuridine.
DB00328
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indomethacin.
DB00352
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tioguanine.
DB00361
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinorelbine.
DB00380
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexrazoxane.
DB00398
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sorafenib.
DB00428
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Streptozocin.
DB00432
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trifluridine.
DB00441
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemcitabine.
DB00444
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teniposide.
DB00445
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Epirubicin.
DB00446
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Chloramphenicol.
DB00480
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lenalidomide.
DB00488
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
DB00495
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Zidovudine.
DB00515
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin.
DB00526
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
DB00531
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclophosphamide.
DB00541
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vincristine.
DB00544
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorouracil.
DB00550
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Propylthiouracil.
DB00552
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pentostatin.
DB00563
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methotrexate.
DB00564
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carbamazepine.
DB00570
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vinblastine.
DB00601
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Linezolid.
DB00619
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Imatinib.
DB00631
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clofarabine.
DB00642
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pemetrexed.
DB00688
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mycophenolate mofetil.
DB00694
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin.
DB00755
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tretinoin.
DB00762
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.
DB00763
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methimazole.
DB00773
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etoposide.
DB00795
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sulfasalazine.
DB00851
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dacarbazine.
DB00853
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temozolomide.
DB00859
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Penicillamine.
DB00864
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tacrolimus.
DB00877
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sirolimus.
DB00888
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mechlorethamine.
DB00928
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Azacitidine.
DB00958
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carboplatin.
DB00970
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dactinomycin.
DB00993
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Azathioprine.
DB00997
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Doxorubicin.
DB01005
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydroxyurea.
DB01008
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan.
DB01024
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mycophenolic acid.
DB01030
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Topotecan.
DB01033
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mercaptopurine.
DB01041
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Thalidomide.
DB01042
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Melphalan.
DB01073
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fludarabine.
DB01097
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Leflunomide.
DB01099
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Flucytosine.
DB01101
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capecitabine.
DB01168
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Procarbazine.
DB01169
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide.
DB01177
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idarubicin.
DB01181
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ifosfamide.
DB01196
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Estramustine.
DB01204
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mitoxantrone.
DB01206
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Lomustine.
DB01229
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paclitaxel.
DB01248
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Docetaxel.
DB01254
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dasatinib.
DB01257
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Eculizumab.
DB01262
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Decitabine.
DB01268
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sunitinib.
DB01280
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nelarabine.
DB01281
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
DB01394
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Colchicine.
DB01423
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Stepronin.
DB01590
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Everolimus.
DB01611
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydroxychloroquine.
DB01816
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Castanospermine.
DB02546
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vorinostat.
DB02806
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
DB03523
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brequinar.
DB04572
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Thiotepa.
DB04845
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ixabepilone.
DB04868
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nilotinib.
DB04951
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirfenidone.
DB04956
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.
DB05015
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belinostat.
DB05109
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trabectedin.
DB05258
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa.
DB05259
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Glatiramer.
DB05260
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gallium nitrate.
DB05459
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Briakinumab.
DB05472
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Human interferon omega-1.
DB05676
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Apremilast.
DB05773
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab emtansine.
DB06168
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Canakinumab.
DB06273
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tocilizumab.
DB06287
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Temsirolimus.
DB06372
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rilonacept.
DB06589
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pazopanib.
DB06603
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panobinostat.
DB06612
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mepolizumab.
DB06616
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib.
DB06643
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Denosumab.
DB06662
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
DB06674
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Golimumab.
DB06681
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belatacept.
DB06769
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bendamustine.
DB06772
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cabazitaxel.
DB06813
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pralatrexate.
DB08059
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Wortmannin.
DB08868
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fingolimod.
DB08870
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin.
DB08871
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Eribulin.
DB08877
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ruxolitinib.
DB08879
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belimumab.
DB08880
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.
DB08889
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Carfilzomib.
DB08895
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tofacitinib.
DB08901
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib.
DB08904
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Certolizumab pegol.
DB08908
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dimethyl fumarate.
DB08910
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.
DB08935
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Obinutuzumab.
DB09029
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Secukinumab.
DB09033
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vedolizumab.
DB09036
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Siltuximab.
DB09052
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Blinatumomab.
DB09053
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibrutinib.
DB09054
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Idelalisib.
DB09073
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.
DB09074
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.
DB09077
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dinutuximab.
DB09082
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Vilanterol.
DB09122
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon beta-1a.
DB09312
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
DB11466
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tepoxalin.
DB11569
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ixekizumab.
DB11580
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ravulizumab.
DB11616
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pirarubicin.
DB11693
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Voclosporin.
DB11708
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peficitinib.
DB11767
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sarilumab.
DB11776
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brodalumab.
DB11803
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sirukumab.
DB11817
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Baricitinib.
DB11834
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Guselkumab.
DB11988
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ocrelizumab.
DB12025
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Triptolide.
DB12371
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Siponimod.
DB12612
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ozanimod.
DB12617
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mizoribine.
DB12692
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gusperimus.
DB12814
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cepeginterferon alfa-2B.
DB12902
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trofosfamide.
DB12947
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Doxifluridine.
DB12991
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deoxyspergualin.
DB12996
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
DB13014
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hypericin.
DB13068
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB13241
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Begelomab.
DB14066
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tetrandrine.
DB14219
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Monomethyl fumarate.
DB14724
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emapalumab.
DB14762
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Risankizumab.
DB14919
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rozanolixizumab.
DB15253
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bleselumab.
DB14039
The risk or severity of adverse effects can be increased when Erenumab is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).
DB00277
The serum concentration of Theophylline can be increased when it is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).
DB00394
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Beclomethasone dipropionate.
DB00588
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluticasone propionate.
DB00591
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocinolone acetonide.
DB01410
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ciclesonide.
DB08906
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluticasone furoate.
DB08970
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB09091
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tixocortol.
DB11487
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone isonicotinate.
DB13223
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortin.
DB13491
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluperolone.
DB13664
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Formocortal.
DB13856
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluclorolone.
DB13867
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluticasone.
DB14512
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mometasone furoate.
DB14539
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone acetate.
DB14545
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone succinate.
DB00180
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Flunisolide.
DB00443
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Betamethasone.
DB00620
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Triamcinolone.
DB00635
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisone.
DB00687
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fludrocortisone.
DB00741
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone.
DB00860
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone.
DB00959
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methylprednisolone.
DB01108
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trilostane.
DB01222
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Budesonide.
DB01234
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dexamethasone.
DB01285
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Corticotropin.
DB01380
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cortisone acetate.
DB01384
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paramethasone.
DB04630
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldosterone.
DB09378
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednisolone.
DB09383
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Meprednisone.
DB11529
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Melengestrol.
DB11921
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deflazacort.
DB13003
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cortivazol.
DB13208
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednylidene.
DB13843
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cloprednol.
DB14681
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cortisone.
DB00253
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Medrysone.
DB00324
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluorometholone.
DB00663
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Flumethasone.
DB00896
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rimexolone.
DB06781
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluprednate.
DB14541
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone cypionate.
DB00873
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Loteprednol.
DB14631
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone phosphate.
DB14633
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone hemisuccinate.
DB14644
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methylprednisolone hemisuccinate.
DB14646
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisone acetate.
DB14652
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clocortolone acetate.
DB14659
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Melengestrol acetate.
DB14669
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Betamethasone phosphate.
DB15566
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone acetate.
DB01013
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clobetasol propionate.
DB01047
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocinonide.
DB14540
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Hydrocortisone butyrate.
DB00547
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Desoximetasone.
DB00764
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mometasone.
DB01260
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Desonide.
DB08971
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluocortolone.
DB11750
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clobetasol.
DB09095
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Difluocortolone.
DB13158
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clobetasone.

序列

实验性质

外部标识符

resource：Drugs Product Database (DPD)
identifier：7940
resource：Drugs Product Database (DPD)
identifier：7941
resource：RxCUI
identifier：235600

外部链接

路径

目标

酶

载体

运输工具

药物反应

效应

不良反应